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Abstract It has previously been shown that the rate of drug
resistance emergence inmedicine is exponential, while we have
been producing drugs at a much lower rate. Our ability to suc-
cessfully contain resistance at any one time is function of how
many drugs we have at our disposal to counter new resistances
from pathogens. Here, we assess our level of preparedness
through a mathematical comparison of the drug manufacture
rate by the pharmaceutical industry with the resistance emer-
gence rate in pathogens. To that effect, changes in the rates of
growth of the drugs production and resistance emergence pro-
cesses are computed over multiple time segments and com-
pared. It is found that new resistance emergence rate in infec-
tious diseases medicine remains mathematically and
permanently ahead of the drugs production rate by the pharma-
ceutical industry. Consequently, we are not in a position to ever
contain current or future strengths of resistance from pathogens.
A review of current practices is called for.
Keywords Antibiotic . Drug . Resistance . Rate . Pathogen .
Pharmaceutical . Infectious . Disease
Background
Once the rate of new resistance emergence in infectious diseases
medicine is known and once the rate of drugs production by the
pharmaceutical industry is also known, we can estimate our level
of preparedness in the face of drug resistance from pathogens.
Based on previously-established statistical models, we can assess
whether we are currently overwhelmed by pathogen resistance or
whether we stand to successfully contain it. Howwell we will be
faring in the near or distant future can also be predicted. Analysis
of the rates gap reveals that we are currently running behind
pathogen resistance and that we also have no chance of overcom-
ing it in the future should we continue with our current
ways—unless required changes are made.
Introduction
Drug resistance has been known to occur to essentially all drugs
designed to target pathogens and, while antibiotics production by
the pharmaceutical industry has come to almost a halt over the
past 30 years [1], renewed efforts are now being made to jump-
start or even accelerate [2] new antibiotics production to replace
old ones rendered ineffective by pathogens. Therefore, it matters
that we be aware of how fast our sustained rate of drugs produc-
tion needs to be in order for us to not fall into another spell of
antibiotics dryness and stay constantly ahead of the game.
Within that framework, we already know that drug resistance
emergence rate, based on pathogen resistance data collected from
a 90-year time period, involving 90 infectious diseases, 118 path-
ogens, and covering 337 molecules, is exponential [3]. And our
approach to overcoming emerged resistance is to manufacture
and introduce new drugs to pathogens. So, in order to remain
prepared and effectively keep drug resistance under control, we
need to be producing drugs at a rate greater than or at least equal
to the rate of new resistance generation by pathogens. But the
question is: Can we sustain an exponential rate of drugs produc-
tion over the long-term?—Here and now, we assess our capacity
to successfully contain resistance with a sustainable rate of anti-
biotics production, based on our current approach to the manage-
ment of infectious diseases.
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Methods
Using the trends shown by predictive statistical models of
drug resistance emergence in infectious diseases medicine,
we estimate our present and future preparedness to effectively
contain resistance and proceed to show how difficult it is
going to be for the medical community to bring resistance
under control. Evaluation of our level of preparedness is based
onmathematical rates comparison of the resistance emergence
process in pathogens with the drugs production process by the
pharmaceutical industry. Antibiotic, drug, ormolecule as used
in this discussion covers all pathogen-killing agents.
Results and discussion
Drug resistance emergence in pathogens has been shown to
occur in layers, each layer being characterized by its own rate
of resistance emergence [3]. The predictive statistical model
which was found to characterize the rate of cumulative first-
layer (i.e., monotherapy) resistance build-up across infectious
diseases medicine, with molecules as a predictor, was [3]:
S1 ¼ 10:90 – 0:417mþ 0:01m2 ð1Þ
where S1 is the cumulative monotherapy resistance and m the
cumulative number of molecules introduced to pathogens.
However, the predictive statistical model which was found
to characterize the rate of cumulative monotherapy (single
molecules) drugs manufactured by the pharmaceutical indus-
try, with time as a predictor, was [3]:
m ¼ −2:312 – 0:428tþ 0:056t2 ð2Þ
where m is the cumulative number of molecules introduced to
pathogens and t elapsed time (years), with 1922 marking year
1.
For all practical purposes, we assume that the trend char-
acterizing both processes (the drugs production and the resis-
tance emergence processes) remains the same into the future.
Having the rates of both processes presented as in Eqs. 1
and 2, let us take a look at what happens in the future between
the number of molecules available to control pathogens and
the number of resistances the pathogens would have
generated.
Drug resistance in the distant future
Here, we shall work with time as a predictor.
For a distant time into the future, t heads to infinity. For
such a distant time, the number of resistant combinations gen-
erated by pathogens and the number of molecules available to
circumvent them would, each, be given by the mathematical
limit of the functions represented by Eqs. 1 and 2 respectively.
In both cases, the limit is calculated to be infinity. However, as
we consider only the time variable and substitute t for m in
Eq. 1, the cumulative resistance S1 becomes a fourth-degree
polynomial with t as a variable (Table 1). Because both pro-
cesses (resistance emergence and drugs production) increase
to infinite levels in the distant future, the prevailing process in
the future will be indicated by the limit of the ratio of both
functions. However,
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So, as time goes by, the first-layer resistance-strengthening
process in pathogens will stay ahead of our drugs production
process. And this only relates to the 1st layer, which we cannot
keep pace with, much less the 2nd, 3rd, 4th,… layers. As a
result, there is not much hope for a successful control of drug
resistance in the distant future.
Table 1: Cumulative monotherapy drug resistance function
Cumulative monotherapy drug resistance as an exponential or
polynomial function
New, yearly drug resistance emergence across infectious diseases
medicine was modeled, and was shown to grow as an exponential
function [3]. But for purposes of the analysis made here, what we
need is cumulative resistance, which is the summation of the new
resistances in all previous years. Because new resistance in each
year is exponential, without even modeling cumulative resistance
per se, the latter can be expressed as the sum of exponentials and
is therefore also an exponential function.
However, although cumulative resistance grows exponentially, it can
also be expressed as a polynomial function (as in Eq. 1) because
the Taylor series expansion of a function, including exponential
functions, allows the said function to be approximated by a sum
of polynomials. So, the exponential cumulative resistance can also be
expressed as a polynomial function. In fact, we have systematically
modeled cumulative monotherapy resistance [3] and have found
that the best model to characterize it is a 2nd-degree polynomial
as shown in Eq. 1, using m as a variable (or a 4th-degree polynomial,
using t as a variable, upon substitution).
To further convince that cumulative monotherapy resistance can accurately
be expressed either as an exponential function or a polynomial function,
a graph of each of those functions is presented, based on real data
(cf. Fig. 1). It can be seen in Fig. 1 that the exponential and polynomial
graphs are essentially identical to each other, showing that cumulative
resistance can be expressed as either one of those two functions.
Drug resistance at the present time
Typically, a new molecule is produced in order to replace an
earlier molecule which has become ineffective due to resis-
tance. However, the earlier molecule together with its target
pathogen made up one resistant pathogen–molecule combina-
tion [3]. The new molecule, together with that same target
pathogen, makes up another pathogen–molecule combination
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which is not yet resistant and is meant to replace the previous
resistant pathogen–molecule combination. Generally, every
new molecule introduced to pathogens by the pharmaceutical
industry is bound to enter a combination with a target patho-
gen, and this new combination is meant to be a replacement
for a previous resistant combination.
Using Eq. 2 above, the cumulative number of molecules
produced by the pharmaceutical industry in 2014 (t = 93) is
expected to be 442 molecules. However, using Eq. 1, the first-
layer cumulative resistance generated by pathogens when 442
molecules have been introduced to them is S1 = 1,782 resis-
tances (1,782 resistant combinations).
From 2014, let us step ahead to 2015 and see what is
happening:
Using Eq. 2, the cumulative number of molecules produced
in 2015 (t = 94) is about 452, meaning that ten new additional
molecules would have been introduced (from 2014 to 2015) to
replace ten combinations which would have become resistant.
Using Eq. 1, however, the first-layer cumulative resistance
generated by the pathogens when 452 molecules have been
introduced to them is S1 = 1,868 resistances—which is 86
resistant combinations more than in 2014.
So, we would be facing 86 new resistant combinations in
2015while wewould have introduced just ten moremolecules
which can replace only ten resistant combinations. We have
10 < 86. The difference is 86–10 = 76. We are going bankrupt.
That result means that the pathogens develop resistance to
more molecules than have been introduced to them: to the ten
molecules introduced (from 2014 to 2015) and to a difference
of 86–10 = 76 theoretical or abstract molecules which
Research & Development might not have created yet. That
is it for the 1-year time slot from 2014 to 2015. We have seen
that the pathogens are bound to stay ahead of us in the distant
future; however, this shows that they are already ahead of us
even at the present time.
Knowing that cumulative resistance build-up is character-
ized by a function (Eq. 1) whose first-order derivative remains
dependent on the variable (t orm), it can be stated that the gap
will keep widening anyway. Therefore, we should expect to
lag farther and farther behind pathogens and to mathematical-
ly never be able to control resistance. This expectation can be
verified with similar calculations for another one-year time
slot; for example, from 2019 to 2020.
The calculations reveal a similar but worse trend:
Using Eq. 2, the cumulative number of molecules
manufactured by the pharmaceutical industry in 2019
(t = 98) is expected to be about 494. However, using Eq. 1,
the first-layer cumulative resistance generated by the patho-
gens when 494 molecules have been introduced to them is
S1 = 2,241 resistances.
In 2020 (t = 99), the cumulative number of molecules
manufactured is expected to be about 504, meaning that ten
new additional molecules would have been introduced to re-
place ten combinations which would have become resistant.
Using Eq. 1, the first-layer cumulative resistance when 504
molecules have been introduced to the pathogens is S1 =
2,343 resistances, which is 102 resistant combinations
more than in 2019.
So, we would be registering 102 additional resistant com-
binations in 2020 while we would have introduced just ten
newer molecules to the pathogens (from 2019 to 2020) to
replace ten previously resistant combinations. We have 10 <
102. The difference is 102–10 = 92, which is even greater than
the difference of 76 obtained for time slot 2014 to 2015. So,
we are going even more bankrupt.
An apparent underlying characteristic of the drug resistance
phenomenon is, therefore, that the pathogens develop resis-
tance tomoremolecules than have been introduced to them. In
this latest example for time slot 2019 to 2020, the pathogens
develop resistance to the ten molecules introduced and to
102–10 = 92 theoretical or abstract molecules which
Research & Development might not have created yet.
For the 2014–2015 time slot, we were bankrupt by 76
outstanding resistances that we were unable to control.
However, for the 2019–2020 time slot, we became even more
bankrupt by 92 outstanding resistances that we cannot control.
As a result, we will try to control those resistances by
manufacturing even more molecules, and the pathogens will
respond to these newer molecules by developing an even
Fig. 1 Cumulativemonotherapy drug resistance inmedicine—expressed
either as a polynomial or as an exponential function. The red graph is the
continued sums of the yearly, exponential, new monotherapy resistances,
R1 [3]. As such, the red graph, representing the cumulative monotherapy
resistance, is also exponential. The blue graph, however, is the graph of
the 4th-degree polynomial function obtained through systematic model-
ing of true observations of cumulative monotherapy resistance data. The
nearly identical shape of the two graphs shows that cumulative monother-
apy resistance in medicine can be expressed either as a 4th-degree poly-
nomial function or as an exponential function
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greater number of resistances. Then, we will try to control
each of those newer resistances by manufacturing even more
molecules, and then the pathogens will respond to these newer
molecules by developing an even greater number of resis-
tances; so forth. This is a dangerous game which will quickly
spiral out of control—and is already doing so. The picture
arising out of this is that the more molecules we introduce to
pathogens, the more dangerous the situation becomes. With
every new molecule we manufacture and put on the market to
control pathogens, resistance gets worse. So, molecules act
exactly like wood feeding the fire that drug resistance constitutes.
Although we may be tempted to think that this situation
characterizes only the first resistance layer (monotherapy
drugs), the situation remains the same across-the-board, for
all the layers of resistance (i.e., for dual-therapy drugs,
triple-therapy drugs, etc.).
On the other hand, knowing that new drug resistance emer-
gence rate in medicine is exponential and that the drug man-
ufacture rate by the pharmaceutical industry, for all practical
purposes, is linear, or, at best, a second-degree polynomial [3],
it could have been seen, without even getting into the above
computations, that, from a mathematical perspective, because
an exponential function grows faster than and stays perma-
nently ahead of a linear one, we will never be able to
control resistance with our current approach, however
disappointing this may be.
However, even if, by some stroke of luck, we were able to
generate drugs at an exponential rate, with coefficients greater
than those of the exponential rate of resistance emergence, the
issue will still remain because molecules nurture resistance de-
velopment in pathogens, and exponentially so— as discussed.
Implications
Among other things, this result means that the pathogens be-
come resistant to molecules ahead of us, ahead of time, and in
an abstract manner. That is, the potential to be resistant to a
molecule develops in the pathogen although that molecule
might not yet be created by R&D. This is dangerous. Why?
—Because the capacity develops in the pathogen but remains
latent, unmanifest. When 10 to 15 years later, we eventually
conceive andmanufacture one of those 76 or 92 (theoretically)
already-resisted molecules and discover that the pathogen is
resistant to it, we would probably call that a case of natural or
intrinsic resistance [4]. However, it is what we could rather
call entrained resistance—because we would have Btrained^
the pathogens to become resistant to that molecule years ear-
lier. This phenomenon partly explains the observation that
some pathogens display resistance to molecules they haven’t
even been exposed to [5], which means that the pathogen has
developed resistance to the molecule prior to having encoun-
tered that molecule in actuality. Entrained resistance favors
such an occurrence. Due to the high (exponential) rate of
resistance emergence in just the first and second layers of
resistance, entrained resistance is an important feature we
need to begin considering.
The situation is devastating not just because of the high
resistance emergence rate but precisely because the very
solution that we have been applying makes the situation even
worse. In fact, the only solution we have had has been to
manufacture new molecules in order to circumvent resistance
developed to previous molecules. However, from the above
discussion, it can be seen that the more molecules we manu-
facture and introduce to pathogens, the more dangerous we
make the situation become. Practically, we are involved in a
competition with pathogens and do not stand to win that com-
petition if something does not change radically in our resis-
tance control strategies. Nevertheless, for those strategies to
change, the understanding underpinning them will also need
to undergo change. Thorough rectification is needed.
What this means is that if we continue to manufacture and
introduce newer and newer molecules to pathogens, we can
expect that the situation will get worse and worse. The com-
petition will be lost regardless of any perspective which may
encourage us to maintain our current practices. For example,
one such perspective currently advocated for resistance con-
trol is to reduce antibiotics use. However, it can be seen from
the foregoing that campaigning for a reduction in antibiotics
use will not stop new resistance emergence but will only delay
it (in time). And then, when it eventually emerges, the increase
in new resistances will be exponential—with entrained resis-
tance right behind it. So, the gap will continue to grow, and
grow abysmal.
In other words, this means that if we recognize the danger
posed by molecule-induced resistance and begin working to-
wards overcoming it, then the solution can no longer be to
produce even more molecules or to re-use old molecules in
novel combinations, which is what we are currently doing.
Such a proposition will hurt and can only hurt because mole-
cules induce resistance in pathogens, and, resistance emer-
gence is an exponential function of the number of molecules
introduced to the pathogens [3]. So, extreme care is needed
here because the above means that the more molecules we
introduce to pathogens, the worse we make their resistance
become.
In fact, what’s happening is something like this: we begin
by introducing one molecule to the pathogens’ system, and,
because resistance emergence rate as a function of molecules
is exponential, they return more than one, let’s say five, new
resistances to us. Then, we manufacture five new molecules
and introduce these to the pathogens in order to control or
circumvent those five new resistances, and get, say, 11 new
resistances back. Then, we manufacture 11 new molecules
and introduce them to the pathogens in order to control or
circumvent those 11 new resistances, and get, say, 25 new
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resistances back. Then, we manufacture 25 new molecules
and introduce them to the pathogens in order to control or
circumvent those 25 new resistances, and get, say, 40 new
resistances back. So on.
How do you control a process like that? —A nightmare
which keeps running out of control.
As a striking, real-life example, it was found that, as of
2007, the medical community had introduced 337 molecules
to the pathogens and that this has generated 1,163 cases of
mono-therapy resistance [3]. So, we’ve gotten roughly three
times more resistances than the number of molecules we have
introduced to the pathogens. Let us now assume that we man-
ufacture and introduce 1,163 new molecules to the pathogens
in order to control/avoid/circumvent those 1,163 resistances.
Assuming the same three-fold rate, we shall be getting rough-
ly 1,163 × 3 ≈ 3,300 new cases of resistance. It keeps on
expanding. How do you contain something that only keeps
expanding? It is not containable.
It can be seen that molecules feed resistance and introducing
moremolecules to the pathogens causes resistance toworsen. So,
our resistance-control approach, as it stands right now, is not
sustainable. As wemove forward with our current understanding
and practices, attempting to control and contain resistance
through a variety of proposed strategies, the realization needs to
occur that resistance can neither be contained nor controlled.
This is because of the second law of resistance, which states that
resistance can only increase to infinite levels if not fully sup-
pressed [6]. Indeed, if each new molecule we introduce to path-
ogens generates a new resistance, AND the only solution we
have had has been to manufacture a newmolecule and introduce
it to pathogens (in order to bypass a pre-existing resistance), then
cumulative resistance can only increase infinitely. This is only
logical. Here, infinite resistance means an infinite number of
resisted molecules—because resisted molecules are what we
are counting. However, we still get infinite resistance even as this
resistance is expressed not in terms of resisted molecules but in
units of resistance [7]. Therefore, we can never contain resistance
because the system is heading to infinity and infinity can not be
contained. No advocated containment strategy can work (and
none has been working!) because the system can only expand
to infinity. This is because of the second law. That no contain-
ment strategy has been working is shown by the fact that the
crisis has only been worsening, as reported by a number of
sources [e.g., 8]. Hopefully, the suggestion made pertaining to
needed changes in drug design [6] will bring the dilemma to
a close and finally give the medical community the upper hand.
As a result of the foregoing, to talk about resistance con-
tainment or control is a mistake—because it is impossible to.
Resistance can neither be contained nor controlled because it
continues to flare up every time a new molecule is introduced
to the pathogens. The immediate implication is that every
effort now being made [8–10] and geared towards the produc-
tion of newer and newer antibiotics (as we currently
understand them) needs to immediately stop. And the sooner
the better, although this may sound hard to digest.
The fact that antibiotic molecules act like wood feeding the
fire that drug resistance constitutes may be counterintuitive but
that’s what’s happening. So, any proposition encouraging the
pharmaceutical industry to produce even more antibiotics (as
we currently understand them), supposedly to help us deal with
pathogen resistance, is dangerous and effectively corners us even
further. It can be expected that the proposition according to
which we will successfully control drug resistance by jump-
starting antibiotics production will not materialize and cannot
materialize. Such a proposition puts populations at greater and
greater risks because of the exponential rise in resistance that new
molecules induce. However, the problem would remain even if
the rate were not exponential but were any other strictly-
increasing mathematical function.
The school of thought on resistance control so far has been to
speed up the discovery and production of newer antibiotics to-
gether with a reduction in antibiotics use [10–13]. Consequently,
while our rate of new molecules production has not been high,
we have been making increased use of combinations of old an-
tibiotics, which also feeds resistance. Furthermore, even as efforts
are now being made worldwide to phase out the routine use of
antibiotics from animal production and save them only for hu-
man use [12], the problem remains and will continue to persist
because the simple fact of using antibiotics, in humans or ani-
mals, is what causes the situation to get worse; the same way
gasoline poured on fire causes the fire to rage even more. In fact,
we have been thinking that it’s the amount used [14, 15]; but it’s
not just the amount used. It is also the simple fact of using; what
matters being the essence of the molecule. We need to come to
grips with this.
The direness of the situation is not only due to how much
antibiotics we are using but also to the simple fact of using
antibiotics (as we currently understand them). This is because
new resistance emergence and cumulative resistance build-up
are, each, both quantity-dependent and molecules-dependent.
In fact, in Eq. 1 and in others [3], molecules alone were found
to be an excellent predictor of cumulative resistance build-up,
although no explanatory variable for quantity (or mass) was pres-
ent in the models. On the contrary, it is now argued that abuse
(meaning quantity) of antibiotics is the culprit [14–17], and the
molecules component is totally ignored. However, the quantity
(say, kilograms) of antibiotics we use is a culprit but not the sole
culprit because cumulative resistance build-up, after being
quantity-dependent (it is dependent on new resistance emer-
gence, and new resistance emergence is quantity-dependent), is
strongly molecules-dependent. Quantity, when it is high (i.e.,
high drug pressure), only acts to shorten the duration required
for the pathogen to develop resistance to the molecule. But then,
once that resistance has emerged, the multiplicity of additional
molecules to which the pathogen simultaneously displays resis-
tance (say, as a result of cross-resistance), leading to an increase
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in the cumulative number of resistedmolecules, is not affected by
the quantity of the molecule used but by the simple fact of having
used that molecule. The essence of the molecule (or drug)
matters.
Let us consider an example to illustrate:
Molecules a and b are of the same class and only molecule
a currently exists, b is not yet manufactured. We’ve been
treating the pathogen with molecule a to the point that resis-
tance develops to it. True, resistance has developed to mole-
cule a because of drug pressure (a given quantity of molecule
a has been applied to the pathogen over time). However, a few
years later, we manufacture molecule b, introduce it to the
pathogen, and discover that the pathogen is resistant to it (a
case of entrained resistance). Question: Has the pathogen
become resistant to molecule b because of drug pressure?
Answer: No, because no quantity of molecule b has been ap-
plied to the pathogen (yet the pathogen has displayed resis-
tance to the molecule). Note needs to be taken that such
cross-resistance can also be conferred to a molecule of a total-
ly different class [18]. Therefore, quantity is not involved in
the spread of pathogen resistance to multiple molecules.
Quantity is indeed involved in the emergence of resistance
to a given molecule; however, it is not involved in the spread
of resistance to other molecules.
Therefore, contrary to current beliefs, supposed abuse (i.e.,
quantity) of antibiotics is not the key culprit for the strengthening
of resistance in pathogens (spread of resistance to other mole-
cules, i.e., more molecules becoming resisted as a result of a
lower number of molecules having been introduced to the path-
ogens). Exposure of pathogens to new molecules is.
Based on this characteristic, even with current safeguards and
programs aimed at reducing quantity of drug pressure on patho-
gens, it is evident that the situation will continue to exacerbate
and there will come a point where wewill not be able to handle it
anymore because the molecule-dependency factor, which is the
key factor involved in the development of resistance to multiple
molecules, is currently being ignored and, worse, turns out to be
an exponential rate factor, as seen [3]. Therefore, the opposite of
the current understanding is true: because the pathogens’ rate of
resistance emergence is alsomolecules-dependent and is greater
than our rate of drugs production, a reduction in the use of anti-
biotics (quantity) can not and will not by itself lead to a subsi-
dence in drug resistance, and the production of more antibiotics
(including the re-use of old antibiotics in new cocktails) will only
make matters worse. At this point, radical and immediate turn-
around is required.
Radical, here, means complete cessation of the use of drugs
or combination drugs aswe currently understand them.Anything
short of that will cost us and will continue to cost us dearly. This
radical turnaround is required because, as seen, for every single
molecule we introduce to pathogens to control or circumvent n
existing cases of resistance, the pathogens return to us n' > n
(new) cases of resistance. So, it is very evident that we are going
bankrupt. Therefore, the turnaround needs to be immediate be-
cause the longer we hold onto our current practices, the tighter
the situation gets.
Although those two (radical and immediate) conditions are
tight ones in and of themselves, the implication of not meeting
them is that resistance will continue to strengthen as we contin-
ue to lag farther and farther behind pathogens in terms of num-
ber of drugs available to combat resistance. Consequences will
be unspeakable. The combination of such tight conditions cer-
tainly makes the situation so difficult to handle. At any rate,
however, the current understanding needs in-depth rectification.
In fact, the only reason why we have been having a hard
time controlling resistance is that there is a law at work (the
first law of resistance) which we have unknowingly been vi-
olating. Abiding now by this law, drug conception as we cur-
rently understand it needs to undergo required changes and be
brought into compliance with Resistance Threshold theory [6]
in order to prevent resistance from arising in the first place.
This will occur once we have understood that resistance is not
specific to just pathogens but is a natural phenomenon
displayed by all living organisms across the biological realm
and is governed by specific laws.
Moving forward, the pharmaceutical industry has been
blamed for not manufacturing antibiotics at a much greater
rate. But it can now be seen that this much-disliked, often-
attacked, low antibiotic production rate is so much beneficial
to us, after all—for had it been higher, resistance would have
been stronger. The opposite of the current situation (i.e., a
higher drugs production rate, conceived according to our cur-
rent understanding) would have strengthened pathogen resis-
tance beyond its current level, making the crisis so muchmore
dire than it currently is.
Conclusion
Comparison of the resistance emergence rate in pathogens
with the drug production rate by the pharmaceutical industry
shows that we have already fallen behind in our quest to con-
tain pathogen resistance. Furthermore, rates comparison re-
veals that it is impossible to win this competition in the future
with the approach we are currently using. From the mathemat-
ics characterizing both the drug production and resistance
emergence processes, it appears that a review of the current
understanding on resistance control is needed. That molecules
feed the strengthening of resistance in pathogens and that this
resistance emerges at an exponential rate, much faster than we
can produce drugs, has the immediate implication that there is
a continuously widening gap between the strength of drug
resistance and our ability to contain it with new molecules.
The new approach, expected to overcome resistance once and
for all, is, however, given by the first law of resistance applied
to drug design [6].
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